255 related articles for article (PubMed ID: 30619281)
1. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
2. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.
Villa-Álvarez M; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; López-Soto A; Payer AR; Gonzalez-Garcia E; Huergo-Zapico L; Gonzalez S
Oncoimmunology; 2017; 6(10):e1353856. PubMed ID: 29123965
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
4. Increased ILT2 expression contributes to dysfunction of CD56
Zhang Y; Tong S; Li S; Wang X; Ren H; Yin W
Antiviral Res; 2022 Sep; 205():105385. PubMed ID: 35917968
[TBL] [Abstract][Full Text] [Related]
5. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.
Huergo-Zapico L; Acebes-Huerta A; Gonzalez-Rodriguez AP; Contesti J; Gonzalez-García E; Payer AR; Villa-Alvarez M; Fernández-Guizán A; López-Soto A; Gonzalez S
PLoS One; 2014; 9(10):e108326. PubMed ID: 25286418
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
7. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
Morel E; Bellón T
J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
[TBL] [Abstract][Full Text] [Related]
8. Cytometry-based analysis of HLA-G functions according to ILT2 expression.
Jacquier A; Dumont C; Carosella ED; Rouas-Freiss N; LeMaoult J
Hum Immunol; 2020 Apr; 81(4):168-177. PubMed ID: 32081570
[TBL] [Abstract][Full Text] [Related]
9. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.
Parry HM; Stevens T; Oldreive C; Zadran B; McSkeane T; Rudzki Z; Paneesha S; Chadwick C; Stankovic T; Pratt G; Zuo J; Moss P
Oncotarget; 2016 Oct; 7(42):68513-68526. PubMed ID: 27655680
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
[TBL] [Abstract][Full Text] [Related]
11. Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer.
Wan R; Wang ZW; Li H; Peng XD; Liu GY; Ou JM; Cheng AQ
Cell Physiol Biochem; 2017; 44(5):1828-1841. PubMed ID: 29224003
[TBL] [Abstract][Full Text] [Related]
12. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
Veuillen C; Aurran-Schleinitz T; Castellano R; Rey J; Mallet F; Orlanducci F; Pouyet L; Just-Landi S; Coso D; Ivanov V; Carcopino X; Bouabdallah R; Collette Y; Fauriat C; Olive D
J Clin Immunol; 2012 Jun; 32(3):632-46. PubMed ID: 22318393
[TBL] [Abstract][Full Text] [Related]
13. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
Front Immunol; 2021; 12():619069. PubMed ID: 34108958
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
